Program
ABBV-547
A development code.
In AbbVie's pipeline, IL-23
. Its studies are mostly in Arthritis, Psoriatic · Psoriasis, led by AbbVie.
Furthest: phase 2, since Mar 4, 20252 company-led studies, 2 open or runningNext primary completion: May 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 22 open or running | phase 2since Mar 4, 2025 | Mar 4, 2025 | May 2028phase 1 · NCT07232004 |
- Named in AbbVie’s own pipeline as
ABBV-547
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 4, 2025First study: phase 2 study in Arthritis, PsoriaticFirst studyNCT06865105 · 300 planned · United States, Canada, Czechia and more
- Nov 14, 2025Phase 1 study in PsoriasisNCT07232004 · 142 enrolled · United States, Japan
- Oct 15, 2026Primary completion moved from 2027-08 to 2028-05Date moved laterphase 1 · +9 months · NCT07232004
- Nov 9, 2026Primary completion moved from 2027-12 to 2029-08Date moved laterphase 2 · +20 months · NCT06865105
Ahead
- May 2028Primary completion: phase 1 study in PsoriasisNCT07232004
- Aug 2029Primary completion: phase 2 study in Arthritis, PsoriaticNCT06865105
TargetBeta
“IL-23”the company's pipeline, read by Claude · source
Other programs on IL23A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risankizumabrule | AbbVie | phase 4 | 68 |
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
| mirikizumabrule | Eli Lilly | phase 4 | 36 |
| SHR-1139 | Jiangsu HengRui Medicine | phase 2 | 8 |
| GSK4528287 | GlaxoSmithKline | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07232004Psoriasis · United States, Japan | 1 | Active, not recruiting | May 2028 | 142 |
| NCT06865105Arthritis, Psoriatic · United States, Canada, Czechia and more | 2 | Recruiting | Aug 2029 | 300 |
How it is read
Names in the registry
- “ABBV-547”, 2 entries
Codes read as this program: ABBV547.
Conditions, from the studies’ own filings
- Arthritis, Psoriatic, 1 study
- Psoriasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.